PUBLISHER: Grand View Research | PRODUCT CODE: 1554024
PUBLISHER: Grand View Research | PRODUCT CODE: 1554024
The global pediatric ENT market size is anticipated to reach at USD 10.17 billion by 2030 and is projected to grow at a CAGR of 5.02% from 2024 to 2030, according to a new report by Grand View Research, Inc. There is an increasing emphasis on early diagnosis and treatment of ENT disorders in children. This awareness drives parents and healthcare providers to seek out advanced diagnostic devices and treatment options, further propelling market growth.
Recent advancements in cochlear implants for pediatric patients include the introduction of the Cochlear Nucleus 8 Sound Processor, which received FDA approval for use in children aged 9 to 24 months in November 2022. This processor is noteworthy for being the most powerful and smallest Behind-The-Ear (BTE) cochlear implant sound processor available, and it has Bluetooth LE Audio technology, allowing direct audio connectivity to consumer electronics. This innovation aims to enhance the listening experience for children by automatically adjusting to environmental changes and reducing background noise during conversations.
Themarket is experiencing growth, significantly influenced by recent FDA approvals and initiatives aimed at enhancing the availability of medical devices specifically designed for children. In December 2023, Acclarent became the first and only company to receive FDA clearance for a new treatment option for children requiring repeat ear tubes.